Innate Pharma (IPHA)
(Delayed Data from NSDQ)
$2.16 USD
+0.01 (0.47%)
Updated Jul 22, 2024 03:59 PM ET
After-Market: $2.25 +0.09 (4.17%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
IPHA 2.16 +0.01(0.47%)
Will IPHA be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for IPHA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for IPHA
All You Need to Know About Innate Pharma (IPHA) Rating Upgrade to Buy
Innate Pharma (IPHA) Gains as FDA Lifts Hold on Lymphoma Study
IPHA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Innate (IPHA) Gains as Blood Cancer Drug Gets Fast Track Tag
Sanofi (SNY) Dupixent Gets CHMP Nod to Eosinophilic Esophagitis
Other News for IPHA
Number of Shares and Voting Rights of Innate Pharma as of June 10, 2024
Innate falls on updated phase 1/2 data on blood cancer asset teamed with Sanofi
Innate Pharma announces updated results from SAR443579/IPH6101
Innate Pharma Shares Updated Results From the Sanofi Developed Blood Cancer Phase 1/2 SAR443579/IPH6101 Trial
Analysts Are Bullish on Top Healthcare Stocks: Accuray (ARAY), Innate Pharma (IPHA)